Sector News

What are the benefits of the digital health revolution?

November 21, 2021
Life sciences

In conversation with Naomi Fried, Ph.D, Founder and CEO of Health Innovation Strategies. 

Andrew Kris 

There has been a trending topic on finding a way to define what digital health is. How do you position digital health? What are those components for you?

Naomi Fried 

The definition that I’m working with my clients on that really seems to resonate is that digital health leverages technology – that’s hardware and software – to deliver care and information to patients and providers that can be more convenient, more cost-effective, and more personalized. Software could include apps, computer programs, games, virtual reality, and chatbots. On the hardware side, it means phones, cell phones, and in particular, computers, but also sensors, wearables, robots, monitors. What’s exciting about digital health is that it has the potential to improve outcomes, decrease costs, improve efficiency, and deliver care and information in entirely new ways because it’s digital.

Andrew Kris 

What do you think the real drivers for digital health are? Is it economic or the enhanced health care component, or a mixture?

Naomi Fried 

It’s certainly a mixture, and one of the things that’s important with digital health innovations is to recognize what the value is. One of the challenges of digital health is that it often requires new business models to think about delivering value in a different way and thinking about who’s going to pay for it.

Andrew Kris 

You wrote an article recently saying in the next few years our healthcare experience will be radically different. How’s that really playing out?

Naomi Fried 

I expect that eventually, healthcare will fully embrace digital health as a safe, effective method for delivering care. I had thought that the adoption of digital health would continue to happen incrementally, but things changed a lot in 2020. COVID-19 has really been almost a discontinuous radical acceleration in the adoption of a lot of areas of digital health. Now, things are happening faster and hotter, and at lower activation energy barriers. I personally have been advocating for telehealth for more than 15 years. Today, we are seeing virtual visits being used everywhere, which is exciting.

Andrew Kris 

I think everybody agrees that this is a really good way to provide better health care. But how does that all fit in with digital health as opposed to the broader concept?

Naomi Fried 

I think it’s the patient care piece that really holds the greatest promise to improve health care. There are four major categories when thinking about patient-facing digital health. The first is diagnosis and evaluation, where providers use clinical-grade, highly specific, digital information that’s generated to evaluate and make decisions about patient care. One example is a company here in the US called nQ Medical, which monitors and evaluates a person’s typing patterns, whether it’s on a keyboard, phone or tablet and uses that test to diagnose and track Parkinson’s disease.

 The second is delivering patient care, virtually, which includes telehealth and remote patient monitoring. Through this, patients can get care where they are, which provides a convenience that really delights patients.

The third area is one that I think is particularly exciting, and not everyone’s heard about, which are digital pharmaceuticals, or “digiceuticals.” They are digital therapeutics that are administered through apps, games, or software, that treat a patient’s condition or disease. For example, today there are apps that can treat depression, attention deficit disorder, insomnia, panic attacks, chronic pain, smoking cessation, the list goes on.

Finally, the fourth category is medication compliance. Again, these are apps, sensors, games, even ingestibles that remind patients to take medication and provide information to doctors or caregivers about a patient’s adherence and compliance.

Andrew Kris 

Recently, telehealth has been getting a huge amount of publicity in the pandemic. Which of these areas you mentioned do you think will have the greatest impact?

Naomi Fried 

Where we’re going to see the biggest growth in digital health will be in digital health diagnostics. We’re already seeing diagnostics for sleep, sleep apnea, pain, Parkinson’s Disease, even things like concussions.

For example, Prevent Biometrics has a mouth guard that athletes can wear to instantly detect a concussion, which then notifies the coach via an app. Mental health is another area where there’s a lot of digital diagnostic work. Sound Health has developed a digital health solution that analyzes a person’s voice and how they are saying something to evaluate their mental health. By identifying the digital biomarkers in a person’s voice, they can measure symptoms of depression or mild traumatic brain injury, or concussion.

Even cancer is being diagnosed with digital health tools. The digital health app, BiliScreen, uses smartphone cameras to detect pancreatic cancer by measuring the bilirubin levels and the whites of a person’s eyes, which is what causes pancreatic cancer patients’ eyes to take on a yellowish tint as their condition becomes more advanced.  What makes BiliScreen special is it can use this camera to detect very low levels of bilirubin, before the yellowing is visible to the naked eye, and indicate possible disease. Ultimately, this is an easier, cheaper diagnostic than a traditional blood test and can be done before any symptoms start to show.

 

comments closed

Related News

March 15, 2024

Novo’s obesity superstar Wegovy wins FDA nod to cut cardio risks in key label expansion

Life sciences

Novo Nordisk’s fast-growing weight loss med Wegovy just added a new cardiovascular FDA approval to its label, likely enabling the med’s superstar status to reach new levels. The med is now the first weight loss treatment to score an FDA nod to reduce the risk of cardiovascular death, heart attack and stroke in adult patients with cardiovascular disease who have obesity or are overweight.

March 15, 2024

Galderma sets price range for supersized $2.6bn IPO in Europe

Life sciences

Galderma has announced a price range of CHF 49 to CHF 53 ($55.8 to $60.3) per share for floatation on the SIX Swiss Exchange. The Swiss skincare company, which revealed its intention to conduct an initial public offering (IPO) earlier in March, will have 40,453,467 new shares available. The offering also consists of 276,909 existing shares.

March 15, 2024

After transformation under new CEO, Leo Pharma touts innovation model and financial progress

Life sciences

Taking over as CEO for an aging company in dire financial straits and in need of a slim-down was a challenging assignment for Christophe Bourdon. But under Bourdon’s watch, Leo Pharma is taking steps toward a rebound. Last month, the 115-year-old Danish private company reported that it cut its operating costs by 14% in 2023 while increasing its revenues by 7%.

How can we help you?

We're easy to reach